[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-metastatic-malignant-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-metastatic-malignant-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100474727","avapritinib-in-the-treatment-of-unresectable-or-recurrent-metastatic-gist-non-exon18-mutations-of-pdgfra-100474727",false,"NCT05461664","Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA","Avapritinib in the Treatment of Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors Non-exon18 Mutations of PDGFRA:A Real-world Study","Inclusion Criteria:\n\n* Patients who are aged ≥ 18 years.\n* Gastrointestinal stromal tumors confirmed by histopathological examination, and CD- and\u002For DOG-1-positive by immunohistochemistry.\n* Presence of mRECIST v1.1-compliant lesions with at least one measurable lesion (non-lymphadenopathy ≥1.0 cm or ≥2-fold scan slice thickness).\n* Treatment with Avapritinib.\n* Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at screening.\n* Patient informed consent and signed written consent form.\n* The patient was compliant and voluntarily scheduled for follow-up, treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* KIT or PDGFRA wild type.\n* Failure to complete continuous atorvastatin for at least 15 days due to intolerability or disease progression.\n* Other serious acute or chronic physical or mental problems, or laboratory abnormalities, may increase the risk associated with participation in the study or use of drugs, or interfere with the judgment of the study results and, in the judgment of the investigator, are not considered appropriate for participation in the investigator.","ALL","18 Years",{"count":19,"type":20},74,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.",[24,25,26],"Gastrointestinal Stromal Tumors","Unresectable Solid Tumor","Recurrent Metastatic Malignant Neoplasm",[28,29],"Avapritinib","Genetic testing","RECRUITING","2025-02-24",{"date":33,"type":34},"2025-02-26","ACTUAL",{"date":36,"type":34},"2022-07-10",{"date":38,"type":20},"2025-12-31",{"name":40,"class":41},"Xinhua Zhang, MD","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":42},"100474974","a-multicenter-study-of-avapritinib-efficacy-and-safety-of-metastatic-or-unresectable-gastrointestinal-stromal-tumors-100474974","NCT05464875","A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors",{"count":19,"type":20},"This is a prospective, multicenter, observational real-world study to explore the therapy patterns and clinical outcomes of Avapritinib in patients with metastatic or unresectable gastrointestinal stromal tumors.",[24,25,26],[28,29],{"date":33,"type":34},{"date":54,"type":34},"2022-07-09",{"date":38,"type":20},{"name":40,"class":41}]